Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

P. Hughes, Timothy; Kaeda, Jaspal; Branford, Susan; Rudzki, Zbigniew; Hochhaus, Andreas; L. Hensley, Martee; Gathmann, Insa; E. Bolton, Ann; C. van Hoomissen, Iris; M. Goldman, John; P. Radich, Jerald

doi:10.1056/nejmoa030513

Public

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Published in New England Journal of Medicine • Oct 8, 2003

Authors:

Timothy P. Hughes

Jaspal Kaeda

Susan Branford

Abstract

BACKGROUND: In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We measured levels of BCR-ABL transcripts in the blood of all patients in this trial who had a complete cytogenetic r...

Subject

Cytarabine

Imatinib

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!